TapewireFind a company

person · Reporting owner

PYOTT DAVID E I

Disclosed activity across 5 companies

Tapewire entity
34936
SEC CIK
0001051578

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132DirectorJune 01, 2026June 03, 2026
BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404DirectorMay 21, 2024May 23, 2024
PLIANT THERAPEUTICS, INC.PLRX · Entity 7022DirectorJune 05, 2025June 10, 2025
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836DirectorSeptember 15, 2026September 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date June 01, 2026 · Filed June 03, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,582 Ending reported balance After 2026-06-01 transaction · row 6
6 source rows · reconciled sequence

Row 1 · 2026-06-01 · Exercise / conversion · Acquired 3,830 · Balance 5,412

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

Row 2 · 2026-06-01 · Sale · Disposed 921 · Balance 4,491

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 3 · 2026-06-01 · Sale · Disposed 1,175 · Balance 3,316

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 4 · 2026-06-01 · Sale · Disposed 1,222 · Balance 2,094

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 5 · 2026-06-01 · Sale · Disposed 495 · Balance 1,599

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Row 6 · 2026-06-01 · Sale · Disposed 17 · Balance 1,582

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $70.20 · Expires 2026-06-03Direct0 Reported balance After 2026-06-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2026-06-01 · Exercise / conversion · Disposed 3,830 · Balance 0

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F7: This stock option was fully vested and exercisable as of June 3, 2017.

Common StockSEC Table I · non-derivativeIndirectby Trust27,900 Reported balance Holding disclosure · report date 2026-06-01 · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · Balance 27,900

F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F6: The shares of ALNY common stock were purchased by the David E I Pyott Trust, of which the reporting person is trustee.

F7: This stock option was fully vested and exercisable as of June 3, 2017.

BIOMARIN PHARMACEUTICAL INC

Report date May 21, 2024 · Filed May 23, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect49,750 Reported balance After 2024-05-21 transaction · row 1
1 source row

Row 1 · 2024-05-21 · Grant · Acquired 4,720 · Balance 49,750

F1: Restricted stock units granted on May 21, 2024. Price not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units granted on May 21, 2024. Price not applicable.

PLIANT THERAPEUTICS, INC.

Report date June 05, 2025 · Filed June 10, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.61 · Expires 2035-06-05Direct30,000 Reported balance After 2025-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2025-06-05 · Grant · Acquired 30,000 · Balance 30,000

F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Tarsus Pharmaceuticals, Inc.

Report date September 15, 2026 · Filed September 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy the David E.I. Pyott Trust9,575 Reported balance After 2026-09-15 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 9,575

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect605 Reported balance After 2026-09-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605

F3: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

F3: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avery Dennison Corp

Report date April 23, 2020 · Filed April 24, 2020

Section 16 reporting ended · disclosed 2020-04-24. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect18,684 Reported balance After 2020-04-23 transaction · row 1
1 source row

Row 1 · 2020-04-23 · Exercise / conversion · Acquired 1,414 · Balance 18,684

2019 Director RSU AwardSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2020-05-01Direct0 Reported balance After 2020-04-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2020-04-23 · Exercise / conversion · Disposed 1,414 · Balance 0

F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected.

Common Stock Units - DDECPSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 1988-08-08IndirectDDECP52,267.5096 Reported balance Holding disclosure · report date 2020-04-23 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance 52,267.5096

Filing footnotes · ownership attribution and instrument terms

F1: Discretionary vesting on last day of Reporting Person's membership on the Issuer's board of directors given service for nearly entire one-year term for which he had been most recently elected.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 15, 2026 Filed Sep 17, 2026 20:47 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionRestricted Stock Units · Derivative 201 $0.00 $0.00
Disclosure

SEC source: 0001051578-26-000010 · wk-form4_1789678066.xml · derivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 605

Underlying: Common Stock · 201 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Read SEC document
September 15, 2026 Filed Sep 17, 2026 20:47 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionCommon Stock 201 Not disclosed Not disclosed
Disclosure

SEC source: 0001051578-26-000010 · wk-form4_1789678066.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By the David E.I. Pyott Trust

Disclosed balance after: 9,575

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2 · balance_after: Includes 1,383 shares previously owned directly that were transferred to the reporting person's trust on May 14, 2026. There was no change in the reporting person's pecuniary interest in the shares.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 20:30 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 806 $0.00 $0.00
Disclosure

SEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 806

Underlying: Common Stock · 806 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F4 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

F4 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 20:30 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 2,417 $0.00 $0.00
Disclosure

SEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,417

Underlying: Common Stock · 2,417 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

F3 · derivative.expiration_date: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 25, 2026 Filed Jun 29, 2026 20:30 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 3,837 $0.00 Strike: $64.34 $0.00
Disclosure

SEC source: 0001051578-26-000008 · wk-form4_1782765056.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,837

Underlying: Common Stock · 3,837 shares

Expires 2036-06-24

F1 · derivative.exercise_date: Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (Right to Buy) · Derivative 3,830 $0.00 Strike: $70.20 $0.00
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · derivative · entry 8

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,830 shares

Expires 2026-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F7 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 3, 2017.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 17 $302.65 $5,145.05
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 6

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,582

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 495 $300.72 $148,856.40
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 5

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,599

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $300.45 to $301.15. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1,222 $299.87 $366,441.14
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 4

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,094

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $299.36 to $300.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 1,175 $298.91 $351,219.25
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,316

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $298.33 to $299.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 921 $297.71 $274,190.91
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,491

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $297.31 to $297.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Read SEC document
June 01, 2026 Filed Jun 3, 2026 20:25 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 3,830 $0.00 $0.00
Disclosure

SEC source: 0001178670-26-000048 · form4.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,412

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on November 12, 2025. The options exercised by the reporting person were due to expire on June 3, 2026.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (Right to Buy) · Derivative 1,441 $0.00 Strike: $298.48 $0.00
Disclosure

SEC source: 0001178670-26-000039 · form4.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,441

Underlying: Common Stock · 1,441 shares

Expires 2036-05-20

F3 · derivative.exercise_date: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
May 20, 2026 Filed May 22, 2026 20:14 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 671 $0.00 $0.00
Disclosure

SEC source: 0001178670-26-000039 · form4.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,582

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:23 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionRestricted Stock Units · Derivative 1,383 $0.00 $0.00
Disclosure

SEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,383 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs vested in full on April 24, 2026, subject to the Reporting Person's continuous service.

Read SEC document
April 24, 2026 Filed Apr 28, 2026 20:23 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 Exercise / conversionCommon Stock 1,383 Not disclosed Not disclosed
Disclosure

SEC source: 0001051578-26-000006 · wk-form4_1777407836.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,383

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F1 · price: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:35 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantRestricted Stock Units · Derivative 3,729 $0.00 $0.00
Disclosure

SEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,729

Underlying: Common Stock · 3,729 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.

F3 · derivative.exercise_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

F3 · derivative.expiration_date: The RSUs will vest in three equal annual installments on March 15th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

Read SEC document
February 18, 2026 Filed Feb 20, 2026 21:35 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 GrantStock Option (right to buy) · Derivative 5,893 $0.00 Strike: $63.27 $0.00
Disclosure

SEC source: 0001051578-26-000004 · wk-form4_1771623346.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,893

Underlying: Common Stock · 5,893 shares

Expires 2036-02-17

F1 · derivative.exercise_date: The option shares will vest in three equal annual installments on February 18th of each of 2027, 2028, and 2029, subject to the Reporting Person's continuous service.

Read SEC document
June 05, 2025 Filed Jun 10, 2025 00:43 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantCommon Stock (Right to Buy) · Derivative 30,000 $0.00 Strike: $1.61 $0.00
Disclosure

SEC source: 0001746473-25-000126 · wk-form4_1749516194.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2035-06-05

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Read SEC document
May 08, 2025 Filed May 12, 2025 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 1,558 $0.00 Strike: $258.35 $0.00
Disclosure

SEC source: 0001735276-25-000063 · edgardoc.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,558

Underlying: Common Stock · 1,558 shares

Expires 2035-05-08

F3 · derivative.exercise_date: The stock option vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
May 08, 2025 Filed May 12, 2025 20:05 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantCommon Stock 775 $0.00 $0.00
Disclosure

SEC source: 0001735276-25-000063 · edgardoc.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 911

F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 20:09 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 7,440 $0.00 Strike: $88.95 $0.00
Disclosure

SEC source: 0001735276-25-000040 · edgardoc.xml · derivative · entry 4

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,440 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025.

F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 18, 2016.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 20:09 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 7,440 $299.00 $2,224,560.00
Disclosure

SEC source: 0001735276-25-000040 · edgardoc.xml · nonDerivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025.

Read SEC document
March 24, 2025 Filed Mar 25, 2025 20:09 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 7,440 $88.95 $661,788.00
Disclosure

SEC source: 0001735276-25-000040 · edgardoc.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,576

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on September 5, 2024. The options exercised and sold by the reporting person were due to expire on December 18, 2025.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 17,560 $0.00 Strike: $88.95 $0.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 10

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,440

Underlying: Common Stock · 17,560 shares

Expires 2025-12-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

F5 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 18, 2018.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 7,470 $0.00 Strike: $71.99 $0.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 9

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,780

Underlying: Common Stock · 7,470 shares

Expires 2027-06-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

F4 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 2, 2018.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionStock Option (right to buy) · Derivative 7,420 $0.00 Strike: $70.20 $0.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · derivative · entry 8

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,830

Underlying: Common Stock · 7,420 shares

Expires 2026-06-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

F3 · derivative.exercise_date: This stock option was fully vested and exercisable as of June 3, 2017.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 7,470 $222.00 $1,658,340.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 6

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 136

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 7,420 $221.00 $1,639,820.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 5

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,606

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 SaleCommon Stock 17,560 $220.00 $3,863,200.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 4

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,026

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 7,470 $71.99 $537,765.30
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,586

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 7,420 $70.20 $520,884.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 2

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,116

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 20:28 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 17,560 $88.95 $1,561,962.00
Disclosure

SEC source: 0001735276-24-000070 · edgardoc.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 17,696

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person on August 11, 2023.

Read SEC document
June 13, 2024 Filed Jun 18, 2024 00:16 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantCommon Stock (Right to Buy) · Derivative 26,764 $0.00 Strike: $13.06 $0.00
Disclosure

SEC source: 0001746473-24-000105 · wk-form4_1718669756.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,764

Underlying: Common Stock · 26,764 shares

Expires 2034-06-13

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 13th, 2024 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 13, 2024 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Read SEC document
May 21, 2024 Filed May 23, 2024 21:36 UTC BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 GrantCommon Stock 4,720 $0.00 $0.00
Disclosure

SEC source: 0001048477-24-000110 · wk-form4_1716500181.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,750

F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable.

Read SEC document
May 16, 2024 Filed May 20, 2024 20:11 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 5,228 $0.00 Strike: $151.22 $0.00
Disclosure

SEC source: 0001735276-24-000055 · edgardoc.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,228

Underlying: Common Stock · 5,228 shares

Expires 2034-05-16

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
June 07, 2023 Filed Jun 8, 2023 21:24 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantStock Option (Right to Buy) · Derivative 14,000 $0.00 Strike: $23.09 $0.00
Disclosure

SEC source: 0001209191-23-035538 · doc4.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 14,000 shares

Expires 2033-06-07

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters following the June 7th, 2023 grant date and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 7th, 2023 grant date, or (ii) the 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Read SEC document
May 23, 2023 Filed May 24, 2023 22:28 UTC BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 GrantCommon Stock 4,190 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-031977 · doc4.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,030

F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:06 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 3,454 $0.00 Strike: $189.87 $0.00
Disclosure

SEC source: 0001735276-23-000068 · edgardoc.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,454

Underlying: Common Stock · 3,454 shares

Expires 2033-05-18

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:13 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionRestricted Stock Units · Derivative 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000018 · edgardoc.xml · derivative · entry 3

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 136 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F3 · derivative.exercise_date: This award vested on February 23, 2023, the first anniversary of the grant date.

F3 · derivative.expiration_date: This award vested on February 23, 2023, the first anniversary of the grant date.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:13 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 Exercise / conversionCommon Stock 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-23-000018 · edgardoc.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
June 16, 2022 Filed Jun 21, 2022 20:22 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantStock Option (right to buy) · Derivative 15,000 $0.00 Strike: $6.80 $0.00
Disclosure

SEC source: 0001567619-22-013200 · doc1.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2032-06-15

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter for three calendar quarters beginning October 1st and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 16, 2022 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

Read SEC document
May 24, 2022 Filed May 27, 2022 01:32 UTC BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 GrantCommon Stock 4,980 $0.00 $0.00
Disclosure

SEC source: 0001567619-22-011800 · doc1.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,840

F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable.

Read SEC document
May 18, 2022 Filed May 20, 2022 20:07 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 5,153 $0.00 Strike: $128.31 $0.00
Disclosure

SEC source: 0001735276-22-000055 · edgardoc.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,153

Underlying: Common Stock · 5,153 shares

Expires 2032-05-17

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
February 23, 2022 Filed Feb 25, 2022 21:08 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantRestricted Stock Units · Derivative 136 $0.00 $0.00
Disclosure

SEC source: 0001735276-22-000028 · edgardoc.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136

Underlying: Common Stock · 136 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock.

F2 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2 · derivative.expiration_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
July 15, 2021 Filed Jul 19, 2021 20:23 UTC ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 GrantStock Option (right to buy) · Derivative 4,032 $0.00 Strike: $171.95 $0.00
Disclosure

SEC source: 0001735276-21-000073 · edgardoc.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,032

Underlying: Common Stock · 4,032 shares

Expires 2031-07-14

F1 · derivative.exercise_date: This award vests in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Read SEC document
June 29, 2021 Filed Jul 1, 2021 00:49 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantStock Option (right to buy) · Derivative 13,286 $0.00 Strike: $28.20 $0.00
Disclosure

SEC source: 0001209191-21-044180 · doc4.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,286

Underlying: Common Stock · 13,286 shares

Expires 2021-06-28

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

Read SEC document
June 29, 2021 Filed Jul 2, 2021 00:14 UTC Amendment PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantStock Option (right to buy) · Derivative 13,286 $0.00 Strike: $28.20 $0.00
Disclosure

SEC source: 0001209191-21-044628 · doc4a.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,286

Underlying: Common Stock · 13,286 shares

Expires 2031-06-28

F1 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable on the first day of each calendar quarter following June 29, 2021 for three calendar quarters and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of June 29, 2021 or (ii) the next annual meeting of the stockholders, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting.

Read SEC document
May 25, 2021 Filed May 28, 2021 00:05 UTC BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 GrantCommon Stock 5,120 $0.00 $0.00
Disclosure

SEC source: 0001567619-21-011320 · doc1.xml · nonDerivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,860

F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable.

Read SEC document
January 12, 2021 Filed Jan 13, 2021 23:15 UTC PLIANT THERAPEUTICS, INC. PLRX · Entity 7022 GrantStock Option (right to buy) · Derivative 26,573 $0.00 Strike: $27.71 $0.00
Disclosure

SEC source: 0000899243-21-001875 · doc4.xml · derivative · entry 1

PYOTT DAVID E I · CIK 0001051578 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,573

Underlying: Common Stock · 26,573 shares

Expires 2031-01-11

F1 · derivative.exercise_date: 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 12, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.